Literature DB >> 21672030

Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.

Giorgos Bamias1, Kostas Evangelou, Theognosia Vergou, Katerina Tsimaratou, Garyfallia Kaltsa, Christina Antoniou, Athanasios Kotsinas, Sungee Kim, Vassilis Gorgoulis, Alexander J Stratigos, Petros P Sfikakis.   

Abstract

TNF is critically involved in the pathogenesis of psoriasis. TL1A is a TNF-like cytokine, which, after binding to death domain receptor DR3, provides costimulatory signals to lymphocytes, amplifies Th1- and Th17-mediated immune responses and induces apoptotic cell death. These functions are inhibited when TL1A associates to decoy receptor DcR3. In the present study, we investigated the expression profiles for TL1A, DR3 and DcR3 in the normal skin and in psoriatic skin lesions. By use of immunohistochemistry, we were able to demonstrate constitutive cutaneous expression of DR3 and DcR3 but not of TL1A in healthy skin. On the other hand, in patients with active psoriasis, we observed abundant immunostaining for TL1A and significant upregulation of its receptors (P < 0.05 in comparison to healthy skin). TL1A, DR3 and DcR3 proteins, as well as mRNA transcripts reflecting in situ production of TL1A and DcR3, were also specifically increased in lesional as compared to non-lesional skin from patients with psoriasis (P < 0.05). These proteins were upregulated in cell populations that are critically involved in the pathogenesis of chronic skin inflammation, such as keratinocytes, macrophages in deep dermis and cells at the perivascular/endothelial area. Finally, we provide evidence for the existence of nuclear localization of TL1A in inflammatory cells from psoriatic lesions. This was also observed in inflamed synovia from patients with rheumatoid arthritis, but not in neoplastic TL1A-expressing cell lines. We conclude that interactions between TL1A and its two receptors may be involved in the pathogenesis of chronic skin inflammation that takes place in psoriasis.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672030     DOI: 10.1111/j.1600-0625.2011.01304.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  26 in total

1.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

2.  Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis.

Authors:  Xiaoli Lou; Yanqiang Hou; Hui Cao; Jingjing Zhao; Fengting Zhu
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

3.  TL1A regulates adipose-resident innate lymphoid immune responses and enables diet-induced obesity in mice.

Authors:  Peter Tougaard; Louise Otterstrøm Martinsen; Ditte Olsen Lützhøft; Henrik Elvang Jensen; Mette Flethøj; Peter Vandenabeele; Anders Elm Pedersen; Søren Skov; Axel Kornerup Hansen; Camilla Hartmann Friis Hansen
Journal:  Int J Obes (Lond)       Date:  2020-01-30       Impact factor: 5.095

Review 4.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

5.  Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1.

Authors:  Yuki Hitomi; Minae Kawashima; Yoshihiro Aiba; Nao Nishida; Mika Matsuhashi; Hitoshi Okazaki; Minoru Nakamura; Katsushi Tokunaga
Journal:  Hum Genet       Date:  2015-04-22       Impact factor: 4.132

Review 6.  The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.

Authors:  Arianne C Richard; John R Ferdinand; Françoise Meylan; Erika T Hayes; Odile Gabay; Richard M Siegel
Journal:  J Leukoc Biol       Date:  2015-07-17       Impact factor: 4.962

7.  Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Authors:  William V Perks; Ravinder K Singh; Gareth W Jones; Jason P Twohig; Anwen S Williams; Ian R Humphreys; Philip R Taylor; Simon A Jones; Eddie C Y Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

Review 8.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

9.  TNFSF15 Modulates Neovascularization and Inflammation.

Authors:  Zhisong Zhang; Lu-Yuan Li
Journal:  Cancer Microenviron       Date:  2012-07-26

10.  Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.

Authors:  Hiroshi Maruyama; Kouichi Hirayama; Miho Nagai; Itaru Ebihara; Homare Shimohata; Masaki Kobayashi
Journal:  Clin Rheumatol       Date:  2016-06-01       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.